MeiraGTx Holdings plc (MGTX) vs MoonLake Immunotherapeutics (MLTX)

A side-by-side comparison of MeiraGTx Holdings plc and MoonLake Immunotherapeutics across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
MeiraGTx Holdings plc logo
MGTX
MeiraGTx Holdings plc
$977M
$10.55HealthcareDelayed quote: Oct 6, 2026, 1:25 PM EDT
MoonLake Immunotherapeutics logo
MLTX
MoonLake Immunotherapeutics
$932M
$11.08HealthcareDelayed quote: Oct 6, 2026, 1:25 PM EDT

Total return — MGTX vs MLTX

growth of $100 · dividends reinvested · last 6y
MGTX -19.4% (-3.5%/yr)MLTX +8.5% (+1.4%/yr)MLTX compounded faster over this window
0200400600Start $100202120222023202420252026$81$108
MGTX MLTX

MGTX vs MLTX: by the numbers

  • •MGTX is the larger company ($977M vs $932M market cap).
  • •MGTX is profitable (19.87% net margin) while MLTX runs a net loss (0.00%).

Metrics side by side

Valuation

MetricMGTXMLTX
P/E ratio14.86N/A
Forward P/E35.17N/A
P/S ratio2.46N/A
P/B ratio4.532.18
EV / EBITDA4.82N/A

Profitability

MetricMGTXMLTX
Gross margin97.19%0.00%
Operating margin-130.20%0.00%
Net margin19.87%0.00%
ROE36.64%-61.58%
ROIC52.81%-50.77%

Growth (annualized)

MetricMGTXMLTX
Revenue CAGR (5Y)84.52%N/A
Total return CAGR (5Y)-3.10%2.81%

Some values include inputs from SEC filing.

Frequently asked

Is MGTX or MLTX more profitable?
MGTX runs the higher net margin — MGTX at 19.87% versus MLTX at 0.00%.
How have MGTX and MLTX total returns compared?
Over the past 5 years, MGTX delivered -3.10% and MLTX delivered 2.81% annualized total return. Past performance doesn't predict future results.

Go deeper

Full MGTX analysisFull MLTX analysisInteractive comparison tool

Dig into the metrics

MeiraGTx P/E ratioMeiraGTx ROEMoonLake Immunotherapeutics ROEMeiraGTx operating marginMoonLake Immunotherapeutics operating marginMeiraGTx revenue growthMoonLake Immunotherapeutics revenue growthMeiraGTx free cash flowMoonLake Immunotherapeutics free cash flow

MeiraGTx & MoonLake Immunotherapeutics appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest ROIC StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.